FIELDS HEIDI
Known title: DirectorCIK: 0001014330
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Agilent to acquire Proscia for up to $270M. Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.
Transaction History
| PHAT | ▲ Buy | Grant | 24,122 | $0 | 5/19/2026 | View on chart |
| PHAT | ▲ Buy | Grant | 10,500 | $0 | 6/3/2025 | View on chart |
| A | ▲ Buy | Grant | 1,819 | $220K | 3/14/2025 | View on chart |
| PHAT | ▲ Buy | Grant | 10,500 | $0 | 5/23/2024 | View on chart |
| A | ▲ Buy | Grant | 1,678 | $247K | 3/15/2024 | View on chart |
| A | ▼ Sell | Open Market | 1,658 | $239K | 3/5/2024 | View on chart |
| PHAT | ▲ Buy | Grant | 9,000 | $0 | 5/25/2023 | View on chart |
| A | ▲ Buy | Grant | 1,658 | $227K | 3/16/2023 | View on chart |
| A | ▼ Sell | Open Market | 3,635 | $566K | 11/23/2022 | View on chart |
| A | ▲ Buy | Grant | 1,785 | $244K | 3/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
PHAT launches Phase 3 study for VOQUEZNA in GERD
Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.
PHAT launches Phase 3 study for VOQUEZNA in GERD. Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.